Access to antivenoms in the developing world: A multidisciplinary analysis

IF 3.6 Q2 TOXICOLOGY Toxicon: X Pub Date : 2021-11-01 DOI:10.1016/j.toxcx.2021.100086
Julien Potet , David Beran , Nicolas Ray , Gabriel Alcoba , Abdulrazaq Garba Habib , Garba Iliyasu , Benjamin Waldmann , Ravikar Ralph , Mohammad Abul Faiz , Wuelton Marcelo Monteiro , Jacqueline de Almeida Gonçalves Sachett , Jose Luis di Fabio , María de los Ángeles Cortés , Nicholas I. Brown , David J. Williams
{"title":"Access to antivenoms in the developing world: A multidisciplinary analysis","authors":"Julien Potet ,&nbsp;David Beran ,&nbsp;Nicolas Ray ,&nbsp;Gabriel Alcoba ,&nbsp;Abdulrazaq Garba Habib ,&nbsp;Garba Iliyasu ,&nbsp;Benjamin Waldmann ,&nbsp;Ravikar Ralph ,&nbsp;Mohammad Abul Faiz ,&nbsp;Wuelton Marcelo Monteiro ,&nbsp;Jacqueline de Almeida Gonçalves Sachett ,&nbsp;Jose Luis di Fabio ,&nbsp;María de los Ángeles Cortés ,&nbsp;Nicholas I. Brown ,&nbsp;David J. Williams","doi":"10.1016/j.toxcx.2021.100086","DOIUrl":null,"url":null,"abstract":"<div><p>Access to safe, effective, quality-assured antivenom products that are tailored to endemic venomous snake species is a crucial component of recent coordinated efforts to reduce the global burden of snakebite envenoming. Multiple access barriers may affect the journey of antivenoms from manufacturers to the bedsides of patients. Our review describes the antivenom ecosystem at different levels and identifies solutions to overcome these challenges.</p><p>At the global level, there is insufficient manufacturing output to meet clinical needs, notably for antivenoms intended for use in regions with a scarcity of producers. At national level, variable funding and deficient regulation of certain antivenom markets can lead to the procurement of substandard antivenom. This is particularly true when producers fail to seek registration of their products in the countries where they should be used, or where weak assessment frameworks allow registration without local clinical evaluation. Out-of-pocket expenses by snakebite victims are often the main source of financing antivenoms, which results in the underuse or under-dosing of antivenoms, and a preference for low-cost products regardless of efficacy. In resource-constrained rural areas, where the majority of victims are bitten, supply of antivenom in peripheral health facilities is often unreliable. Misconceptions about treatment of snakebite envenoming are common, further reducing demand for antivenom and exacerbating delays in reaching facilities equipped for antivenom use.</p><p>Multifaceted interventions are needed to improve antivenom access in resource-limited settings. Particular attention should be paid to the comprehensive list of actions proposed within the WHO Strategy for Prevention and Control of Snakebite Envenoming.</p></div>","PeriodicalId":37124,"journal":{"name":"Toxicon: X","volume":"12 ","pages":"Article 100086"},"PeriodicalIF":3.6000,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a7/bb/main.PMC8578041.pdf","citationCount":"27","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Toxicon: X","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590171021000229","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"TOXICOLOGY","Score":null,"Total":0}
引用次数: 27

Abstract

Access to safe, effective, quality-assured antivenom products that are tailored to endemic venomous snake species is a crucial component of recent coordinated efforts to reduce the global burden of snakebite envenoming. Multiple access barriers may affect the journey of antivenoms from manufacturers to the bedsides of patients. Our review describes the antivenom ecosystem at different levels and identifies solutions to overcome these challenges.

At the global level, there is insufficient manufacturing output to meet clinical needs, notably for antivenoms intended for use in regions with a scarcity of producers. At national level, variable funding and deficient regulation of certain antivenom markets can lead to the procurement of substandard antivenom. This is particularly true when producers fail to seek registration of their products in the countries where they should be used, or where weak assessment frameworks allow registration without local clinical evaluation. Out-of-pocket expenses by snakebite victims are often the main source of financing antivenoms, which results in the underuse or under-dosing of antivenoms, and a preference for low-cost products regardless of efficacy. In resource-constrained rural areas, where the majority of victims are bitten, supply of antivenom in peripheral health facilities is often unreliable. Misconceptions about treatment of snakebite envenoming are common, further reducing demand for antivenom and exacerbating delays in reaching facilities equipped for antivenom use.

Multifaceted interventions are needed to improve antivenom access in resource-limited settings. Particular attention should be paid to the comprehensive list of actions proposed within the WHO Strategy for Prevention and Control of Snakebite Envenoming.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
发展中国家抗蛇毒血清的获取:多学科分析
获得针对地方性毒蛇品种的安全、有效、有质量保证的抗蛇毒血清产品是最近为减轻全球蛇咬伤负担而进行的协调努力的一个重要组成部分。多重准入障碍可能影响抗蛇毒血清从制造商到患者床边的旅程。我们的综述描述了不同水平的抗蛇毒血清生态系统,并确定了克服这些挑战的解决方案。在全球一级,制造产量不足以满足临床需求,特别是用于生产者稀少地区的抗蛇毒血清。在国家层面,某些抗蛇毒血清市场的资金不稳定和监管不足可能导致采购不合格的抗蛇毒血清。当生产商未能在应该使用其产品的国家寻求其产品的注册,或者在薄弱的评估框架允许在没有当地临床评估的情况下进行注册时,情况尤其如此。蛇咬伤受害者的自付费用往往是抗蛇毒血清的主要资金来源,这导致抗蛇毒血清使用不足或剂量不足,以及不顾疗效而偏爱低成本产品。在资源有限的农村地区,大多数受害者被咬伤,外围卫生设施的抗蛇毒血清供应往往不可靠。对蛇咬伤治疗的误解很常见,这进一步减少了对抗蛇毒血清的需求,并加剧了到达配备抗蛇毒血清使用设施的延误。在资源有限的环境中,需要采取多方面的干预措施来改善抗蛇毒血清的获取。应特别注意世卫组织预防和控制蛇咬伤战略中提出的综合行动清单。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Toxicon: X
Toxicon: X Pharmacology, Toxicology and Pharmaceutics-Toxicology
CiteScore
6.50
自引率
0.00%
发文量
33
审稿时长
14 weeks
期刊最新文献
A polygeneric immunogen composed of 22 venoms from sub-Saharan African snakes to expand the neutralization scope of the EchiTAb-plus-ICP antivenom Stress levels, hematological condition, and productivity of plasma-producing horses used for snake antivenom manufacture: A comparison of two industrial bleeding methods Diagnosis of human envenoming by terrestrial venomous animals: Routine, advances, and perspectives Supplementation of polyclonal antibodies, developed against epitope-string toxin-specific peptide immunogens, to commercial polyvalent antivenom, shows improved neutralization of Indian Big Four and Naja kaouthia snake venoms Bioprospection of rattlesnake venom peptide fractions with anti-adipose and anti-insulin resistance activity in vitro
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1